GliaPharm's pioneering approach is to stimulate the neuroprotective action of glial cells to treat certain types of neurological and psychiatric disorders. These pathologies, which all share similar glial and metabolic dysfunctions, include Alzheimer's disease, mild cognitive impairments (MCI), amyotrophic lateral sclerosis (ALS) and depression. GliaPharm has established a drug discovery platform, GliaX™, centered on glial cells activity and brain metabolism. The company is developing its pipeline program to establish a new class of agents for neuroprotection and maintenance of cognitive functions.
While the importance of glial cells has been overlooked in drug development so far, it is now clear that these cells play a key role in sustaining brain function and neuroprotection. Targeting glial cells hence represents an innovative approach for the treatment of neurological and psychiatric disorders based on strong scientific evidence.
Schematic representation of the functional connectivity between neurons, astrocytes and a capillary in the brain